These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 21447431)
1. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Marzaro G; Chilin A; Guiotto A; Uriarte E; Brun P; Castagliuolo I; Tonus F; González-Díaz H Eur J Med Chem; 2011 Jun; 46(6):2185-92. PubMed ID: 21447431 [TBL] [Abstract][Full Text] [Related]
2. Improvement of multivariate image analysis applied to quantitative structure-activity relationship (QSAR) analysis by using wavelet-principal component analysis ranking variable selection and least-squares support vector machine regression: QSAR study of checkpoint kinase WEE1 inhibitors. Cormanich RA; Goodarzi M; Freitas MP Chem Biol Drug Des; 2009 Feb; 73(2):244-52. PubMed ID: 19207427 [TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors. Zeng H; Zhang H J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293 [TBL] [Abstract][Full Text] [Related]
4. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity. Verkhivker GM Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284 [TBL] [Abstract][Full Text] [Related]
5. A neural network-based QSAR approach for exploration of diverse multi-tyrosine kinase inhibitors and its comparison with a fragment- based approach. Ajmani S; Viswanadhan VN Curr Comput Aided Drug Des; 2013 Dec; 9(4):482-90. PubMed ID: 24138419 [TBL] [Abstract][Full Text] [Related]
6. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors. Tintori C; Magnani M; Schenone S; Botta M Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033 [TBL] [Abstract][Full Text] [Related]
7. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome. Martin E; Mukherjee P J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092 [TBL] [Abstract][Full Text] [Related]
8. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Ravindra GK; Achaiah G; Sastry GN Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839 [TBL] [Abstract][Full Text] [Related]
9. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834 [TBL] [Abstract][Full Text] [Related]
10. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity. Martin E; Mukherjee P; Sullivan D; Jansen J J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971 [TBL] [Abstract][Full Text] [Related]
11. Theoretical studies of QSAR and molecular design on a novel series of ethynyl-3-quinolinecarbonitriles as SRC inhibitors. Fang DQ; Wu WJ; Zhang R; Zeng GH; Zheng KC Chem Biol Drug Des; 2012 Jul; 80(1):134-47. PubMed ID: 22429605 [TBL] [Abstract][Full Text] [Related]
12. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. Du J; Lei B; Qin J; Liu H; Yao X J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278 [TBL] [Abstract][Full Text] [Related]
13. Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR. Lan P; Sun JR; Chen WN; Sun PH; Chen WM J Enzyme Inhib Med Chem; 2011 Jun; 26(3):367-77. PubMed ID: 20846090 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132 [TBL] [Abstract][Full Text] [Related]
15. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610 [TBL] [Abstract][Full Text] [Related]
16. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176 [TBL] [Abstract][Full Text] [Related]
17. Structural biology contributions to tyrosine kinase drug discovery. Cowan-Jacob SW; Möbitz H; Fabbro D Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462 [TBL] [Abstract][Full Text] [Related]
18. Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico. Shih KC; Lin CY; Zhou J; Chi HC; Chen TS; Wang CC; Tseng HW; Tang CY J Chem Inf Model; 2011 Feb; 51(2):398-407. PubMed ID: 21182293 [TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors. Lan P; Chen WN; Xiao GK; Sun PH; Chen WM Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873 [TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis. Qin J; Lei B; Xi L; Liu H; Yao X Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]